Sep 2026· Japan Journal of Clinical & Medical Research· Vol 6, pp. 1· 0 citations
TL;DR
This comprehensive review and quantitative meta-analysis systematically decipher the multisystem biology of HF across four interconnected pillars: structural and subcellular myocardial remodeling, immunometabolic reprogramming, extracellular matrix (ECM) dynamics and fibrosis, and interorgan crosstalk.
Abstract
Heart failure (HF) has traditionally been conceptualized as a primary hemodynamic pump failure characterized by reduced cardiac output and compensatory fluid retention. Modern translational science, however, reveals HF to be a systemic, multi-organ syndrome driven by interconnected maladaptive pathways. This comprehensive review and quantitative meta-analysis systematically decipher the multisystem biology of HF across four interconnected pillars: structural and subcellular myocardial remodeling, immunometabolic reprogramming, extracellular matrix (ECM) dynamics and fibrosis, and interorgan crosstalk (the cardiorenal, cardiohepatic, metabolic, and central nervous system axes).Through a systematic search of PubMed/MEDLINE, EMBASE, and Web of Science (2015–2026), we extracted quantitative metrics across 84 clinical cohorts and preclinical models (N = 42,680). Meta-analytic pooling demonstrates that microvascular endothelial inflammation and immunometabolic signaling (e.g., NLRP3 inflammasome activation, IL-1$\beta$/IL-6 signaling, and metabolic substrate switching from mitochondrial fatty acid oxidation to inefficient glycolysis) directly correlate with phenotypic progression in both HF with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction (HFrEF). Furthermore, we quantify the impact of key systemic interventions—including SGLT2 inhibitors, GLP-1 receptor agonists, mineralocorticoid receptor antagonists, and targeted anti-inflammatory agents—on reversing adverse cardiac remodeling and dampening systemic interorgan decay.
Heart failure with preserved ejection fraction (HFpEF) represents a predominant heart failure phenotype characterized by intricate pathophysiology and an escalating global prevalence. Beyond classical hemodynamic disturbances, emerging evidence identifies mitochondrial dysfunction as a central mechanism in HFpEF pathog...
Ying An, Cong-Hui Shang, A. M. Abd el-Aty et al.· The Journal of Cardiovascula...· 0 citations
Background Heart failure with preserved ejection fraction (HFpEF) accounts for half of all heart failure cases. However, its complex pathophysiology, which is characterized by bidirectional interactions among immune, metabolic, and mechanical pathways, has long resisted a simple explanation. Approach Rather than listin...
Kai-Jian Zhang, Hui Li, Wei-Na Wen et al.· International Journal on Bio...· 0 citations
Hypertension is a highly prevalent clinical condition and a major contributor to global cardiovascular morbidity and mortality. Despite extensive research, its complex and multifaceted pathogenesis is yet to be fully elucidated. This paper explores the updated understanding of primary hypertension as a systemic disorde...
Dima Nasrallah, Alaa Abdelhamid, Omar Tluli et al.· Journal of Cellular Physiolo...· 0 citations
Summary Heart failure (HF) is a multisystem syndrome in which myocardial dysfunction is shaped by metabolic, vascular, and extracardiac abnormalities. Across HFrEF and HFpEF, impaired substrate utilization, mitochondrial function, endothelial signaling, coronary microvascular function, and mechano-energetic coupling di...
Heart failure with preserved ejection fraction (HFpEF) represents an entity distinct from heart failure with reduced ejection fraction (HFrEF), driven by highly heterogeneous and systemic pathophysiological mechanisms. Conventional biomarkers such as NT-proBNP primarily indicate hemodynamic stress and remain inad...
G. H. Nam, S. Kang, D. Cho· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.